David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,308
Out of 4,667 analysts
6
Total ratings
n/a
Success rate
-61.27%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Initiates: Buy | $5,200 | $2.28 | +227,970.18% | 1 | Aug 7, 2023 | |
| STSS Sharps Technology | Initiates: Buy | $352 | $2.73 | +12,807.48% | 1 | May 9, 2023 | |
| ATXI Avenue Therapeutics | Initiates: Buy | $2,400 | $1.97 | +121,727.41% | 1 | Apr 3, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $1.28 | +915.63% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $2.49 | +4,759.44% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Aug 7, 2023
Initiates: Buy
Price Target: $5,200
Current: $2.28
Upside: +227,970.18%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $352
Current: $2.73
Upside: +12,807.48%
Avenue Therapeutics
Apr 3, 2023
Initiates: Buy
Price Target: $2,400
Current: $1.97
Upside: +121,727.41%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $1.28
Upside: +915.63%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $2.49
Upside: +4,759.44%